Hormonal
Circulating Adipocyte Fatty Acid–Binding Protein (A-FABP) levels are significantly elevated in overweight and obese individuals and correlate positively with components of metabolic syndrome, including insulin resistance, dyslipidemia, and hypertension.
This research highlights that Adipocyte Fatty Acid–Binding Protein (A-FABP) is a circulating marker that rises with obesity and correlates with metabolic risks like insulin resistance and high blood pressure. While measuring A-FABP is not a standard clinical test for weight loss, the findings reinforce that excess adipose tissue actively contributes to metabolic dysfunction through secreted proteins. Managing body weight and reducing visceral fat are the primary levers to lower these biomarkers and improve metabolic health.
Mean (SD) circulating concentrations of A-FABP were significantly higher in overweight/obese than in lean persons [32.3 (14.8) vs 20.0 (9.8) (cid:1)g/L; P <0.001]. Age- and sex-adjusted serum A-FABP concentrations correlated positively (P <0.005) with waist circumference, blood pressure, dyslipidemia, fasting insulin, and the homeostasis model assessment insulin resistance index.
Why this rating
Large sample size (n=229), rigorous proteomic identification, and statistically significant correlations, though it is a cross-sectional observational study.
Source
Adipocyte Fatty Acid–Binding Protein Is a Plasma Biomarker Closely Associated with Obesity and Metabolic Syndrome
Aimin Xu et al. · Clinical Chemistry · 2006
DOI 10.1373/clinchem.2005.062463
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →